Humacyte/$HUMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Humacyte
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
- Ticker
- $HUMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 184
- Headquarters
- Durham, United States
- Website
- www.humacyte.com
Humacyte Metrics
BasicAdvanced
$191m
-
-$0.56
2.31
-
Price and volume
Market cap
$191m
Beta
2.31
52-week high
$2.55
52-week low
$0.55
Average daily volume
6.2m
Financial strength
Current ratio
3.929
Quick ratio
3.025
Long term debt to equity
546.051
Total debt to equity
566.939
Interest coverage (TTM)
-8.32%
Profitability
EBITDA (TTM)
-105.185
Gross margin (TTM)
-4,053.72%
Net profit margin (TTM)
-4,840.82%
Operating margin (TTM)
-5,579.76%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-51.48%
Return on equity (TTM)
-409.47%
Valuation
Price to revenue (TTM)
61.546
Price to book
13.56
Price to tangible book (TTM)
13.56
Price to free cash flow (TTM)
-1.212
Free cash flow yield (TTM)
-82.51%
Free cash flow per share (TTM)
-0.586
Growth
Revenue change (TTM)
289.94%
Earnings per share change (TTM)
-15.51%
3-year revenue growth (CAGR)
14.81%
3-year earnings per share growth (CAGR)
25.55%
What the Analysts think about Humacyte
Analyst ratings (Buy, Hold, Sell) for Humacyte stock.
Humacyte Financial Performance
Revenues and expenses
Humacyte Earnings Performance
Company profitability
Humacyte News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.